FDA chief Janet Woodcock acknowledges agency may have misstepped in process leading up to Alzheimer’s drug approval
Woodcock said the FDA may have been able to improve how it handled the process leading up to its approval of Biogen’s new Alzheimer’s drug.
Read The Story
